**SYNOPSIS**

**On**

# *DEVELOPMENT AND OPTIMISATION OF A NOVEL IONICALLY CROSS-LINKED NANOPARTICLES AND ITS PHARMACEUTICAL APPLICATIONS*


***Submitted by***

**Mr. Vivek Verma**

**(University Roll No.- 2117650020002)**

**Under the Supervision of**

**Dr. T S Easwari**


***For the partially award of the degree***

***of***

**DOCTOR OF PHILOSOPHY**


***Department Of Pharmacy***

***IIMT College of Medical Sciences***

IIMT UNIVERSITY
MEERUT


**IIMT UNIVERSITY**

**Meerut**

**Introduction:**

Rheumatoid joint inflammation (RA) is a persistent, even, provocative immune system sickness that starts in little joints & advances to skin, eyes, heart, kidneys & lungs. Joint bone & ligament are oftentimes annihilated, ligaments & tendons debilitate. All of this joint harm brings about deformations & bone disintegration, which are normally intensely excruciating for patient. Morning firmness of impacted joints for over 30 minutes, weakness, fever, weight reduction, delicate, enlarged, and warm joints, rheumatoid knobs under the skin are normal side effects of RA.

Disease typically shows up b/w the ages of 35 and 60, with times of abatement & fuel. It can like-wise influence small kids before the age of 16, which is known as adolescent RA (JRA), which is like RA with the exception of that no rheumatoid component is**.** The pervasiveness of RA in the West is assessed to be 1-2% & 1% around the world.

Clinically, RA varies from osteo-arthritis (OA) in that impacted regions in RA are proximal inter-phalangeal (PIP) & meta-carpo-phalangeal (MP) joints, while OA commonly influences distal inter-phalangeal (Plunge) joint. The most well-known kind of joint pain is osteoarthritis (OA), which is brought about by mileage instead of an immune system condition. It isn't hurtful to the lungs, heart, & invulnerable framework. Moreover, not at all like RA, which is even, OA regularly influences just a single side of body. Another recognizing highlight is that RA patients experience persevering morning firmness for no less than 60 minutes. Morning firmness is normal in OA patients, however it typically resolves or diminishes inside 20-30 minutes.

The EULAR proposals for early joint pain the board ***(Combe et al, 2015)*** were refreshed in 2016 to assist with administration of vague however thought synovitis even before determination of distinct rheumatoid joint inflammation & another joint problem. As per these rules, patients who present with joint pain (any joint enlarging joined by torment &

firmness) ought to see a rheumatologist in no less than about a month & a half of side effect beginning. To help board choices, risk factors for tireless & erosive illness, like quantity of enlarged joints, intense stage reactants, rheumatoid variable, and hostile to citrullinated protein immune response focus, ought to be assessed. In numerous centers, ultrasound is regularly used to decide if joints are dynamic (i.e., positive power Doppler signal), however in an early rheumatoid joint pain trial **,** a treat-to-target system utilizing ultrasound direction was found to have no additional advantage contrasted with a methodology dependent exclusively upon clinical discoveries, while in another study**,** ultrasound gave added benefit. Patients who are in danger of creating persevering joint pain ought to start DMARD treatment quickly. Smoking end, dental consideration, wt. control, immunization status appraisal, & comorbidity executives ought to all be important for generally speaking patient consideration



**Advantages of Nanoparticles:**

- They have more drug loading capacity and stability as compare to solid lipid nanoparticles.
- Nano Lipid Carriers have the feasibility of incorporating both hydrophilic and lipophilic drugs.
- Biocompatible and biodegradable lipids employed in their fabrication minimize toxicity issues.
- Nano Lipid Carriers can serve as promising tool for enhancing therapeutic efficacy of drugs and also providing controlled release of encapsulated drugs.
- This smart drug delivery carrier creates flexibility for modulation of drug release
- It provides prevention of drug expulsion during targeting.

**Problem Statement**

1. Multidose Therapy with conventional formulation
2. Patient non-compliance
3. The high cost of traditional formulation
4. Improved Bioavailability.
5. Minimising side-affects.

**Objectives of Study:**

1. To Formulate Nanoparticles of drug.
2. Improved Drug Control and Targeted Action
3. Formulation of nanoparticles with high drug encapsulation efficiency
4. Reduced *in- vivo* toxicity.

## Hypotheses Formulation

- Reduction in cost of Arthritic treatment is the main focus for selection of proposed work.
- Desire to do something for the nation & to get respectability.
- To reduced adverse effects of high dose of Arthritic drug by reduced dosing frequency.

**Literature Review:**

Several organs and synovial tissues with distinct systemicsymptoms are implicated in the disease. The interaction of tendonsheaths and ligaments with the synovial lining gives rise to pain,swelling, increased redness, and stiffness. Ligament activity in thecervical region can cause pain and neurological signs ofsubluxation. The joints' articular surfaces and their surroundingsoft tissues induce the cardinal joint's manifestations that areultimately responsible for the crippling disorganization of the jointinvolved. The degrees

of physical disabilities are directlyproportional to these alterations. Pain, tenderness, discomfort,erythema, and effusion begin with them. They progress tocartilage wear and tear, stiffness and osteoporosis, if not managed,resulting in subluxation and dislocation of the joint. Compared tothe other joints, the wrist, the elbow, metacarpophalangeal, andknee joints are engaged early in most patients. The condition ofthe patient is further compounded by the gradual weakening of themuscle groups (***Joshi &Kotwal, 2011***).

***Gary M et al, 2017****,* announced the objective of treatment for patients recently determined to have RA ought to keep joint harm from creating by utilizing early & forceful ways to deal with treatment that limits sickness action. Similarly for laid out infection treatment ought to be pointed toward restricting movement of existing joint harm. Significant advances have been made in treatment of RA throughout course of recent many years, by & large because of better comprehension of science of RA & resultant presentation of biologic treatments. There is nobody side effect, lab measure & clinical apparatus that gives genuinely exact evaluation of sickness action in patients with RA.

**Christine T et al (2015),** Presumed that rheumatoid joint pain (RA) is a typical provocative sickness portrayed by moderate bone & ligament obliteration, bringing about serious utilitarian constraints, abbreviated life expectancy, & expanded death rates. New treatment approaches have fundamentally deferred illness movement & worked on the personal satisfaction for some patients. However couple of patients achieve & can be kept up with in sickness reduction without constant resistant suppressive therapy. In expansion a sizable piece of patients likewise neglects to answer & in long run creates resilience to current treatments. In this manner there is a proceeded with need for improvement of new restorative methodologies for treatment of RA. In contrast to regular medications, nano-systems are intended to convey helpful specialists explicitly to site of irritation, hence staying away from

potential foundational & off-target undesirable impacts. They permit examiners to consider or reevaluate restorative specialists that were recently considered too harmful to even think about conveying through a foundational course. This article surveys ongoing nano-technology-based methodologies that are being created for treatment of provocative joint inflammation.

Simarpreet Kaur et al: Nanotechnology mediated drug delivery has been reported to enhance the drug efficacy, bioavailability, reduce toxicity and improve patient compliance by targeting the cells and tissues to produce desired pharmacological action. Aim: The purpose of the present study was to formulate and evaluate rivastigmine loaded chitosan nanoparticles for sustained release. Conclusion: The experimental results showed the suitability of chitosan nanoparticles as a potential carrier for providing sustained delivery of rivastigmine[7].

***Chabib L et al, (2018)*** showed late advances in science & innovation profoundly altered manner in which we identify, treat & forestall various illnesses in all parts of human existence. Rheumatoid joint pain is a persistent, foundational, moderate, immune system illness in which body's safe framework whose significant job is to safeguard the wellbeing by going after unfamiliar microscopic organisms & infections are erroneously, going after joints bringing about thickened synovium, pannus development, obliteration of bone, ligament. Still now analysts can't have foggiest idea about specific reason for this sickness. It is accepted that qualities & ecological variables assume a part being developed of RA. In this survey, we examine Patho-physiology, indicators, & variables associated with pathogenesis of RA. We likewise talk about Customary restorative specialists for Rheumatoid Joint inflammation. All the more critically, we broadly talk about the arising novel medication conveyance frameworks (NDDS) like nanoparticles, dendrimers, micelles, micro-spheres, liposomes, etc as these are the promising apparatuses having effective applications in beating restrictions related with customary medication conveyance frameworks. Albeit a few

NDDS have been utilized for different purposes, liposomes have been centeredaround because of its expected applications in RA conclusion & treatment. Moreover, we talk about remedial viability & difficulties for RA by utilizing these clever medication conveyance frameworks. At last, we finish up by examining the future viewpoints.

**Chegini S et al, (2018);** audited that RA is ongoing fiery illness with complex pathology-characterized by aggravation of joints, demolition of synovium, pannus arrangement, bones and ligament obliteration & frequently is related with diligent ligament torment, expanding, firmness & work handicap. In customary RA treatment, due to short natural half-life, unfortunate bio-availability, high & regular dosing is required. Accordingly those enemy of RA prescriptions, which can't specifically target impacted zone, may cause serious aftereffects in extra-articular tissues. Today nanotechnology has arisen as promising apparatus being developed of novel medication conveyance frameworks for treatment & finding of immovable illnesses like RA. Dynamic focusing in RA nano-medication has likewise been presented an effective way for working with explicit admission of helpful specialists by illness cells. Different designated drug conveyance frameworks utilized for RA determination & treatment.

## PLAN OF WORK

**1. Preformulation Studies**

i) Identification of drug

a) UV Spectroscopy

b) IR Spectroscopy

c) Melting Point

ii) Solubility Studies (By using different solvents)

iii) Partition Coefficient (log P)

iv) Drug Excipient Compatibility Studies (By FTIR techniques)

**2. Formulation Development**

i) Selection of Polymers

ii) Optimization of Drug dose

iii) Selection of methods for Nanoparticles

a) High pressure homogenization

b) Solvent dispersion

**3. Characterization of formulations**

i) Particle Size

ii) Particle Morphology (SEM)

iii) Zeta potential

iv) Entrapment Efficiency

v) Drug Content

*vii) In -Vitro* drug release studies of formulation

viii) *In –Vitro release* kinetics studies (Zero order, First order, Hixson Crowell cube root, Higuchi release kinetics)

**4.** Stability Analysis (as per ICH guidelines)

**5.** Computation and compilation

## EQUIPMENT'S REQUIRED

Various types of research equipment's are used during the production of nanostructured lipid carriers in the research laboratory**:**

- Rotatory Flash evaporator
- Homogenizer
- Scanning Electron Microscopy (SEM)
- Transmission Electron Microscopy (TEM)
- Differential scanning calorimetry (DSC)

- Ultra Violet Spectrophotometer

- Fourier Transmission Infrared Spectrophotometer (FTIR)

**Expected Contributions of the Study**

1. Better entrapment of the drug
2. Good Controlled diffusion profile of drug
3. Reduced side-effect/ Adverse effects associated with conventional drug delivery system.

## REFERENCES


1. OliveiraI.M , Cristiana G., "Engineering nanoparticles for targeting rheumatoid arthritis: Past, present, and future trends" Nano Research 2018, 11(9): 4489–4506.

2. Ahmad J, Sarasija S, "Formulation, Characterization and In Vitro Evaluation of Methotrexate Solid Lipid Nanoparticles" Research Journal of Pharmacy and Technology 2(4):685-689 · December 2009

3. Singh D and Harikumar S L and Nirmala: Nanoparticles :An Overview, Journal of Drug delivery and therapeutics 2013;3(2):169-175

4. Ahmad O E, Mageh W H, Wael M S, and Nazik A E: Novel ionically crosslinked casein nanopartciles for Flutamide delivery: formulation and In-vivo pharmacokinetics: Int J Nanomedicine. 2013;8:1721-32. doi: 10.2147/IJN.S40674. Epub 2013 May 3.

5. Natarajan T, Chellan VR, Krishnamoorthy B and Siram K: Brain targeted delivery of rivastigmine polymeric Nanoparticles through oral administration to treat Alzheimer's disease. In. J. of Research in Ph. and Nano Sci. 2014; 3(6): 536-551

6. Kaur SP, Rekha Rao R, Afzal Hussain A, Kaur SK, Khatkar S: Preparation and Characterization of Rivastigmine Loaded Chitosan Nanoparticles: J. Pharm. Sci. & Res. Vol.3(5), 2011,1227-1232

7. Ruby J, Pandey V P: Chitosan Nanoparticles As A Nasal Drug Delivery For Memantine Hydrochloride: International Journal of Pharmacy and Pharmaceutical Sciences, ISSN- 0975-1491, Vol 7, Issue 1, 2015.

8. Catarina P R,Neufeld R J, Nanoencapsulation I.Methods for preparation of drug-loadedpolymericnanoparticles: Nanomedicine: Nanotechnology, Biology, and Medicine 2 (2006) 8–21.

9. RENU TIRUWA: A review on nanoparticles –preparation and evaluation parameters: Indian Journal of Pharmaceutical and Biological Research (IJPBR), 2015; 4(2):27-31.

10. A E Koch: Angiogenesis as a target in rheumatoid arthritis Ann Rheum Dis. 2003 Nov; 62(Suppl 2): ii60–ii67.

11. Khaira R, Sharma J, and Saini V: Development and Characterization ofNanoparticles for the Delivery of Gemcitabine Hydrochloride, Scientific World Journal, 2014 Jan 24: 560962

12. Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer